Deutsche Bank AG Boosts Stock Position in NeuroPace, Inc. $NPCE

Key Points

• Deutsche Bank AG increased its stake in NeuroPace, Inc. by 124.0% in the first quarter, holding approximately 2.82% of the company valued at $11,359,000.
• Analysts are optimistic about NeuroPace, with several firms setting a "buy" rating and average price targets ranging from $15.00 to $18.00.
• Despite achieving revenues of $23.52 million in the last quarter, NeuroPace reported a loss of ($0.26) earnings per share, missing analyst expectations.

Deutsche Bank AG boosted its holdings in shares of NeuroPace, Inc. (NASDAQ:NPCE - Free Report) by 124.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 924,274 shares of the company's stock after purchasing an additional 511,662 shares during the quarter. Deutsche Bank AG owned about 2.82% of NeuroPace worth $11,359,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Geode Capital Management LLC raised its stake in NeuroPace by 1.8% during the 4th quarter. Geode Capital Management LLC now owns 322,973 shares of the company's stock valued at $3,615,000 after purchasing an additional 5,781 shares during the period. Northern Trust Corp increased its stake in NeuroPace by 15.7% in the 4th quarter. Northern Trust Corp now owns 184,847 shares of the company's stock worth $2,068,000 after acquiring an additional 25,035 shares during the last quarter. Essex Investment Management Co. LLC bought a new stake in NeuroPace in the 1st quarter worth approximately $1,701,000. Jane Street Group LLC bought a new stake in NeuroPace in the 4th quarter worth approximately $1,120,000. Finally, JPMorgan Chase & Co. increased its stake in NeuroPace by 440.4% in the 4th quarter. JPMorgan Chase & Co. now owns 64,826 shares of the company's stock worth $725,000 after acquiring an additional 52,829 shares during the last quarter. Institutional investors own 78.83% of the company's stock.

NeuroPace Trading Down 1.4%

Shares of NeuroPace stock traded down $0.1150 on Tuesday, reaching $8.3050. The company had a trading volume of 40,022 shares, compared to its average volume of 274,561. The firm has a market cap of $274.73 million, a price-to-earnings ratio of -9.89 and a beta of 1.89. The company has a debt-to-equity ratio of 3.02, a current ratio of 5.47 and a quick ratio of 4.51. The firm's 50-day moving average price is $9.82 and its two-hundred day moving average price is $11.66. NeuroPace, Inc. has a 1 year low of $5.45 and a 1 year high of $18.98.

NeuroPace (NASDAQ:NPCE - Get Free Report) last announced its earnings results on Tuesday, August 12th. The company reported ($0.26) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The company had revenue of $23.52 million during the quarter, compared to analysts' expectations of $23.08 million. NeuroPace had a negative return on equity of 168.61% and a negative net margin of 29.29%. NeuroPace has set its FY 2025 guidance at EPS. As a group, research analysts predict that NeuroPace, Inc. will post -1 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research firms have issued reports on NPCE. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $17.00 price objective on shares of NeuroPace in a research note on Wednesday, May 14th. JPMorgan Chase & Co. lifted their price objective on NeuroPace from $14.00 to $16.00 and gave the stock an "overweight" rating in a research note on Wednesday, May 14th. Zacks Research downgraded NeuroPace from a "strong-buy" rating to a "hold" rating in a research note on Wednesday, August 13th. Wells Fargo & Company reduced their price objective on NeuroPace from $17.00 to $15.00 and set an "overweight" rating on the stock in a research note on Wednesday, August 13th. Finally, HC Wainwright began coverage on NeuroPace in a research note on Wednesday, May 28th. They issued a "buy" rating and a $18.00 price objective on the stock. Five research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company's stock. Based on data from MarketBeat, NeuroPace presently has a consensus rating of "Moderate Buy" and an average target price of $16.60.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.